GLP-1 Drugs

iShares' Healthcare and Pharmaceuticals ETFs Share Fees as Fidelity's FHLC Undercuts Rivals

Recent fund comparisons show fee parity at iShares while cost, concentration and yield gaps should guide whether investors favor broad low‑cost ETFs or concentrated drugmaker exposure.